If there is a single small molecule that keeps showing up in serious longevity conversations, it is rapamycin. In the decade since the National Institute on Aging's Interventions Testing Program first showed that rapamycin extends mouse lifespan even when dosing begins in middle age, the drug has graduated from niche geroscience curiosity to the most discussed off-label longevity intervention in the world. This article is an evidence-first review of what we actually know about rapamycin longevity claims in 2026 — which data are robust, which are extrapolated, and who should probably stay away.
What Is Rapamycin?
Rapamycin (sirolimus) is a macrolide compound originally isolated in 1972 by Suren Sehgal and colleagues from Streptomyces hygroscopicus, a soil bacterium collected on Rapa Nui (Easter Island) — the source of the drug's name. Sehgal initially characterized it as an antifungal. It turned out to be far more interesting than that. By the 1990s, rapamycin had been approved by the FDA (1999) as an immunosuppressant to prevent kidney transplant rejection, and a decade later was approved in drug-eluting coronary stents and for the rare disease lymphangioleiomyomatosis.
The molecular target of rapamycin is literally named after the drug: mTOR (mechanistic target of rapamycin), a master kinase that integrates nutrient, growth factor, and energy signals to control protein synthesis, cell growth, and autophagy. mTOR exists in two complexes — mTORC1 (rapamycin-sensitive, acutely) and mTORC2 (only inhibited by chronic exposure). This distinction turns out to matter enormously for dosing strategies.
The longevity story began in 2009, when the NIA Interventions Testing Program published in Nature that rapamycin extended the lifespan of genetically heterogeneous mice even when started at 20 months of age — the mouse equivalent of a 60-year-old human. That paper (Harrison, Strong, Sharp, Nelson, Astle, Flurkey, Nadon, Wilkinson, Frenkel, Carter, Pahor, Javors, Fernandez, Miller — Nature 2009;460:392–395) was a genuine turning point.
How Rapamycin Works
Rapamycin binds the intracellular protein FKBP12, and the FKBP12–rapamycin complex then binds mTORC1, inhibiting its kinase activity. The downstream consequences include:
- Reduced protein synthesis via inhibition of S6K1 and 4E-BP1 phosphorylation
- Increased autophagy — cells clean up damaged organelles and aggregated proteins
- Reduced lipogenesis and anabolism — energy is diverted from growth toward maintenance
- Modulated immune function, especially T-cell proliferation
In evolutionary terms, mTOR is the "grow when food is abundant, conserve when it isn't" switch. Pharmacologically tricking cells into thinking nutrients are scarce mimics aspects of caloric restriction, which is the most reproducible lifespan-extending intervention ever discovered. This mechanistic logic is why rapamycin is considered the most promising caloric restriction mimetic currently in human use.
The critical nuance: chronic daily rapamycin also hits mTORC2 in many tissues, which is where most of the metabolic side effects (glucose intolerance, new-onset diabetes in transplant recipients) are thought to originate. Intermittent dosing — weekly or every-other-week — may preserve mTORC1 inhibition (the longevity-relevant signal) while sparing mTORC2. This is the rationale behind nearly every off-label rapamycin protocol in use today.
The Evidence
Mouse data: robust and replicated
The 2009 Harrison et al. ITP paper showed median lifespan extension of 9% in males and 14% in females when rapamycin was started at 20 months. Follow-up ITP papers (Miller et al. 2011, 2014; Strong et al. 2020) replicated the effect across three independent labs — the gold standard for preclinical reproducibility — and demonstrated a dose-response relationship, with higher doses producing larger lifespan gains (up to ~23% median extension in females at the highest dose tested). Rapamycin is, as of 2026, the only pharmacological intervention to produce robust, reproducible, late-life lifespan extension in mammals in the ITP.
Importantly, the extension is not merely lifespan — healthspan markers (tendon stiffness, cardiac function, cognition in some studies) also improve. Short courses of rapamycin (3 months) in middle-aged mice have been reported to produce lasting benefits, hinting at hit-and-run pharmacology that has fueled intermittent dosing enthusiasm.
Human data: early but growing
- PEARL trial (Mannick et al., earlier everolimus work 2014/2018; Kaeberlein-led PEARL rapamycin trial 2023–2024): The PEARL (Participatory Evaluation of Aging with Rapamycin for Longevity) trial was a decentralized, placebo-controlled study in healthy adults. Initial results presented in 2024 suggested modest benefits in lean mass and self-reported measures in women, without dramatic safety signals at the tested intermittent doses (5–10 mg weekly).
- Mannick everolimus trials (2014 Science Translational Medicine; 2018 Science Translational Medicine): Joan Mannick and collaborators at Novartis showed that the rapalog everolimus improved influenza vaccine response in older adults and reduced respiratory tract infections — the first hard human evidence that mTOR inhibition can rejuvenate an aging immune system.
- Dog Aging Project / TRIAD (Kaeberlein, Promislow): The Test of Rapamycin In Aging Dogs trial is studying middle-aged companion dogs. Preliminary echocardiography data have suggested improvements in age-related cardiac function, and the larger TRIAD efficacy arm is ongoing.
- RAP PAC and related cardiac trials: Small studies exploring rapamycin in age-related cardiac and metabolic phenotypes have reported feasibility and acceptable safety with intermittent dosing.
No human trial has yet demonstrated a mortality reduction. That is an important honest caveat.
What Researchers and Clinicians Are Doing Today
The off-label rapamycin community in 2026 is anchored by a handful of clinician-researchers. Matt Kaeberlein (formerly University of Washington, now leading Optispan) is probably the most cited voice. Kaeberlein publicly discontinued his own rapamycin use after developing suspected side effects, and has been careful to frame rapamycin as "the most promising geroscience drug we have, but the human evidence is still thin." Alan Green, a New York physician, has been prescribing rapamycin off-label to thousands of patients since 2017 and publishes case-series observations (not RCT-quality data) on the protocol.
Typical off-label protocols involve 5–8 mg once weekly, sometimes titrated by trough levels, with lab monitoring every 3–6 months for lipids, glucose, HbA1c, CBC, and CMP. Some clinicians cycle on and off to reduce cumulative exposure.
Who should almost certainly NOT take rapamycin off-label:
- Anyone with active infection or recent bacterial/viral illness
- People who are immunosuppressed for other reasons
- Patients with poorly controlled diabetes (rapamycin can worsen glucose tolerance)
- Anyone scheduled for surgery or wound-healing situations
- Women trying to conceive or who are pregnant
- People on multiple interacting medications (rapamycin is metabolized by CYP3A4)
Reported side effects at intermittent longevity doses include mouth ulcers (aphthous stomatitis), acneiform rash, lipid changes, mild anemia, and occasional insulin resistance. Serious immunosuppression is uncommon at weekly low doses but is not zero, which is why blanket recommendations remain inappropriate.
Connection to Gene Editing and Peptides
Rapamycin sits upstream of many of the biological processes that other longevity interventions target from different angles. Autophagy activation — rapamycin's signature effect — overlaps with the mitochondrial quality control pathways targeted by mitochondrial peptides like MOTS-c. Both push cells toward maintenance over growth, but through different entry points.
Rapamycin also complements the broader hallmarks of aging framework by addressing deregulated nutrient sensing, one of the nine original hallmarks. Researchers increasingly view it as a "stack partner" to interventions that address other hallmarks — senolytics for cellular senescence, partial reprogramming for epigenetic drift, and peptides for specific tissue-level repair. For broader context on how these fit together, see our peptides for longevity beginners guide and the complete guide to what peptides are.
Gene editing intersects with rapamycin in an unexpected place: several gene therapy trials use short-term rapamycin to blunt immune responses against AAV capsids, improving transgene persistence. In other words, the same drug being used for longevity off-label is also a quiet enabler of durable gene editing.
Limitations and What We Don't Know
- No human lifespan or mortality data. All the lifespan evidence is in mice. Mouse-to-human translation for lifespan interventions has a mediocre track record.
- Optimal dose and schedule are unknown. Weekly 5 mg is convention, not evidence. The right dose may vary by body weight, age, and goal (immune rejuvenation vs. metabolic vs. cognitive).
- Long-term safety at longevity doses is not characterized. Transplant safety data use far higher daily doses and don't translate cleanly.
- Biomarker surrogates are imperfect. Changes in epigenetic age, IGF-1, inflammatory markers, or grip strength don't reliably predict lifespan benefit.
- Selection bias in off-label user cohorts. People who take rapamycin off-label tend to be healthier, wealthier, and more engaged in their own health — making anecdotal outcomes impossible to interpret.
FAQ
Does rapamycin extend lifespan in humans?
We don't know. It extends lifespan robustly in mice and improves immune function in older adults, but no human trial has measured mortality.
What dose of rapamycin do longevity clinicians use?
Most off-label protocols use 5–8 mg once weekly, sometimes adjusted by blood trough levels. These doses are empirical, not evidence-based.
Is rapamycin safe for long-term use?
At transplant doses (daily, continuous), it causes meaningful side effects. At weekly intermittent doses used for longevity, the safety profile appears more favorable in short-term data, but long-term RCT data do not yet exist.
Can rapamycin reverse biological age?
Some small studies suggest modest epigenetic age reductions, but these are not lifespan endpoints and the measurements themselves carry uncertainty.
Who popularized rapamycin for longevity?
Mikhail Blagosklonny's theoretical papers from 2006 onward, followed by the ITP mouse lifespan data in 2009, drove the field. Matt Kaeberlein and Alan Green are the most public clinical voices today.
Is rapamycin a caloric restriction mimetic?
Partially. It targets mTORC1, one of the central nutrient-sensing hubs affected by caloric restriction, but it does not reproduce every CR-associated adaptation.
